β³ Fetching live dividend data...
Home βΊ Calculator βΊ IUGNF Dividend Calculator 2026
Imugene Limited Β· OTC
Price: $0.06 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
IUGNF is not a dividend-focused stock
IUGNF pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Imugene Limited (IUGNF) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another cancer vaccine designed to induce the body to generate polyclonal antibodies that block PD-1 signaling. Additionally, they are developing CF33, a potent oncolytic virus constructed from a unique combination of genomic sequences sourced from various vaccinia virus strains. Imugene has forged a research collaboration with Celularity Inc. to integrate its CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for the treatment of solid tumors. Furthermore, the company maintains a strategic partnership with Eureka Therapeutics, Inc. Established in 1986, Imugene Limited is headquartered in Sydney, Australia.
No. Imugene Limited (IUGNF) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. IUGNF has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open IUGNF position with:
Real after-tax yield depends on where you live and how you hold IUGNF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
IUGNF pays quarterly β 4 times per year. Ex-div: β.
How IUGNF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IUGNF sourced from FMP /financial-growth endpoint β real data, not estimates.
Compare IUGNF with peers: IUGNF vs BSEM Β· IUGNF vs CLTEF Β· IUGNF vs HSCHF
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IUGNF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Imugene Limited (IUGNF) is currently trading at $0.06, 80% below its 52-week high. It does not currently pay a regular dividend.
Imugene Limited (IUGNF) is a healthcare stock trading at $0.06. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever